Home » Topics » Science » New compound

New compound
RSS

Novel GLP-1 receptor agonist with improved oral bioavailability

June 16, 2022

T3SS inhibitor MBX-5452 well tolerated and reduces bacterial load in pneumonia mouse model

June 15, 2022

DA-1726 shows efficacy in diet-induced NASH mouse model

June 14, 2022

Cilagicin, next-generation antibiotic with activity against MDR isolates

June 9, 2022

Atux Iskay presents preclinical data on PP2A activator ATUX-792 in IPF

May 30, 2022

CHIN-117 reduces inflammation in murine model of colitis

May 27, 2022

MT-101: a potent and small molecule alpha4beta7 integrin inhibitor

May 25, 2022

Allorion Therapeutics presents TYK2 inhibitor ARTS-011 for the treatment of inflammatory disease

May 13, 2022

Discovery of potent and orally bioavailable CSNK1A1 inhibitors

May 10, 2022

Discovery of GB-1101, selective oral HDAC6 inhibitor with potent antitumor activity in vivo

May 9, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...